Our Team
Simon Elliott
Simon Elliott is a senior managing director in Evercore’s healthcare strategic advisory business based in London. Having joined Evercore in 2013, he has worked extensively with clients across the healthcare subsectors, including pharma, biotech, medtech and healthcare services for c. 20 years.
Recent notable transactions include advising Novartis on the sale of “front-of-eye” ophthalmology assets to Bausch + Lomb; Bristol-Myers Squibb on its acquisition of Mirati Therapeutics; Takeda on its acquisition of Nimbus Therapeutics; Novo Nordisk on its acquisition of Dicerna and Emisphere Technologies; AstraZeneca on its acquisition of Alexion; Nestle on the sale of its allergy portfolio, the sale of Galderma (Nestle Skin Health) and the acquisition of Zenpep; Philips on its acquisitions of BioTelemetry and Capsule Technologies; Sanofi on its acquisition of Principia Biopharma; Eli Lilly on its acquisition of Dermira (and subsequent sale of Qbrexza); Bristol-Myers Squibb on its acquisition of Celgene; AstraZeneca on the sale of its anti-infections business to Pfizer; AstraZeneca on its defense against Pfizer; Shire on its acquisition of Baxalta International; Takeda Pharmaceutical on its acquisition of Shire and subsequent sale of Xiidra to Novartis; Takeda on its acquisition of Ariad Pharmaceuticals; and Partners Group and Duke Street on the acquisition of Voyage Care.
Mr. Elliott received a master’s in biochemistry from the University of Oxford.